Means Investment CO. Inc. Has $4.31 Million Position in Novo Nordisk A/S (NYSE:NVO)

Means Investment CO. Inc. cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,140 shares of the company’s stock after selling 1,837 shares during the period. Means Investment CO. Inc.’s holdings in Novo Nordisk A/S were worth $4,313,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. DAVENPORT & Co LLC lifted its holdings in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after purchasing an additional 451,641 shares during the last quarter. Wellington Management Group LLP bought a new position in Novo Nordisk A/S during the third quarter worth $42,017,000. Finally, World Investment Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Down 1.2 %

NVO stock opened at $84.36 on Monday. The company has a market cap of $378.56 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The business has a 50-day simple moving average of $93.56 and a 200 day simple moving average of $113.03.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.